Arrox

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

89 API Suppliers, 21 USDMF, 15 CEP/COS, 8 JDMF, 16 EU WC, 32 KDMF, 21 NDC API, 37 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

83 Drugs in Development

83 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

377 FDF Dossiers, 64 FDA Orange Book, 106 Europe, 36 Canada, 34 Australia, 44 South Africa, 93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 3 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 7 Kirsch Pharma, 4 ACG Worldwide, 7 Actylis, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 20 BASF, 1 CD Formulation, 7 DFE Pharma, 7 Gangwal Chemicals, 2 Ideal Cures, 4 Ingredion Pharma Solutions, 16 Kerry, 3 Keval Exports, 3 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 Ulanqab Kema New Material, 4 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

60 Fillers, Diluents & Binders, 40 Disintegrants & Superdisintegrants, 35 Direct Compression, 31 Granulation, 24 Thickeners and Stabilizers, 20 Lubricants & Glidants, 17 Taste Masking, 15 Chewable & Orodispersible Aids, 15 Coating Systems & Additives, 15 Parenteral, 13 Co-Processed Excipients, 12 Film Formers & Plasticizers, 11 Controlled & Modified Release, 10 Solubilizers, 8 Empty Capsules, 7 Topical, 5 Rheology Modifiers, 4 Emulsifying Agents, 3 API Stability Enhancers, 2 Surfactant & Foaming Agents, 2 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 55 News #PharmaBuzz

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 39 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

35 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

81 US Patents, 4 US Exclusivities, 12 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 20 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 20938 / DOSAGE - TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
MELOXICAM(UNII: VG2QF83CGL) (MELOXICAM - UNII:VG2QF83CGL)	MELOXICAM	7.5mg

Setid Dbbc6373 E9ae 4215 8d08 5f6667a936d1 Applno 20938 Form Tablet Oral Dosage 15mg - Drug Product Composition: Arrox

Arrox

Arrox

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

89 API Suppliers

21 USDMF

15 CEP/COS

8 JDMF

16 EU WC

32 KDMF

21 NDC API

37 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

83 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

377 FDF Dossiers

64 FDA Orange Book

106 Europe

36 Canada

34 Australia

44 South Africa

93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem

1 Evonik

3 Rochem International Inc

8 SPI Pharma

11 DKSH

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

7 Kirsch Pharma

4 ACG Worldwide

7 Actylis

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

20 BASF

1 CD Formulation

7 DFE Pharma

7 Gangwal Chemicals

2 Ideal Cures

4 Ingredion Pharma Solutions

16 Kerry

3 Keval Exports

3 Lonza Capsugel

12 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Novo Excipients

5 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

1 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

4 Silverline Chemicals

2 Ulanqab Kema New Material

4 Vasa Pharmachem

2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

TABLET;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons